IP Library › Patent Application 11358601
Patent Application
App. No. 11/358,601

Chemical compounds

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/358,601
Abstract

The present invention discloses compounds of Formula I. The present invention also discloses beta-3 agonists of formula I and methods for treating beta-3 mediated diseases and condition using the compounds of formula I, in particular methods for treating diabetes or obesity.

Claims (30)

1 . A method for the prevention or treatment of clinical conditions or diseases susceptible to amelioration by administration of an atypical beta-adrenoceptor agonist, comprising administration of an effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof:

wherein X is oxygen or sulfur, and where the heterocycle containing X is substituted meta or para to the depicted NH;

R 1 is hydrogen or C 1-6 alkyl;

R represents substituents selected from C 1-6 alkyl, halogen, trifluoromethyl, and

C 1-6 alkoxy; and

n represents an integer from 0-4.

2 . The method of claim 1 wherein said condition or disease is obesity.

3 . The method of claim 1 wherein said condition or disease is urinary incontinence.

4 . A method for the prevention or treatment of obesity comprising administration of an effective amount of a compound selected from:

2-( 3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)furan-3-carboxylic acid;

2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)furan-3-carboxylic acid;

2-( 4-{2R-[2-(3-Chlorophenyl)-2R-hydroxylethylamino]propylamino}phenyl)furan-3-carboxylic acid;

2-(3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)thiophene-3-carboxylic acid;

2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino)phenyl)thiophene-3-carboxylic acid;

2-( 4-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)thiophene-3-carboxylic acid;

or pharmaceutically acceptable derivatives thereof.

5 . The method of claim 4 wherein the compound is selected from 2-(3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)furan-3-carboxylic acid;

2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)thiophene-3-carboxylic acid;

or pharmaceutically acceptable derivatives thereof.

6 . A method for the prevention or treatment of urinary incontinence comprising administration of an effective amount of a compound selected from:

2-( 3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)furan-3-carboxylic acid;

2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)furan-3-carboxylic acid;

2-( 4-{2R-[2-(3-Chlorophenyl)-2R-hydroxylethylamino]propylamino}phenyl)furan-3-carboxylic acid;

2-( 3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)thiophene-3-carboxylic acid;

2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)thiophene-3-carboxylic acid;

2-( 4-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)thiophene-3-carboxylic acid;

or pharmaceutically acceptable derivatives thereof.

7 . The method of claim 6 wherein the compound is selected from 2-(3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)furan-3-carboxylic acid;

2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)thiophene-3-carboxylic acid;

or pharmaceutically acceptable derivatives thereof.

Assignments (1)
SECURITY INTEREST Recorded Oct 7, 2019
From: VELICEPT THERAPEUTICS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 050642/0074 →